Loading
Absci Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 06 Jul 2026.
Absci Corp: what insiders have been doing
Absci Corp is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 34 filings came from 11 insiders.
Purchases and sales both appear in the filings: 4 purchases (4 insiders, €631k) and 2 sales (2 insiders, €112k). Netting one side against the other leaves €519k of net buying. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a purchase of €198k from Busch Andreas, disclosed on 16 March 2026. Those buying include 4 senior executives.
In the case of 1 purchase, another manager of the company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last purchase on record was published on 6 July 2026, which is 104 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4.
For context, the typical company on the same exchange (median of 5,811 companies) published 19 filings over the same period, against 34 filings here. The full history, which starts in 2021, counts 16 purchases against 3 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 2.8 m USD and net income at -115.2 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
98
Thresholds
n/a
Buy Volume
€2M
16 ops. · all time
Sell Volume
€13M
3 ops. · all time
Who traded when
BuySaleAndreas Busch2 buys
Menelas N. Pangalos2 buys
Frans van Houten1 buy
Mary T. Szela1 buy
Sean McClain1 sale
Todd Bedrick1 buy
+1 other insider
Since the insiders bought
- -21.6%Entry US$11.33 · Close 15 Oct 2026 US$8.88
- +139.9%Entry US$3.03 · Close at T+90 US$7.27
- +138.7%Entry US$2.66 · Close at T+90 US$6.35
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Absci Corp Strong Buy (bullish), based on 10 analysts. Average price target: US$14.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$8.74
Analyst consensus
10 analystsStrong buy
US$10.00Target US$14.50(+66%)US$17.00
Income statement
RevenueUS$2.8M
EBITDA-US$103.2M-3684% margin
Net income-US$115.2M-4113.7% margin
Valuation
PER (forward)-12.9x
P/Book6.1x
Beta2.28
Balance sheet & cash
Market capUS$1.5B
Total debtUS$5.3M
Free Cash Flow-US$94M
Debt / Equity2%
Profitability & ownership
ROE-57.7%
ROA-34.1%
% insiders11.8%
% institutions87.4%
Last declaration on 14 October 2026
Declarations98 total
23,293 shares@ US$10.160.014% mcap22.8% of flowCommon StockSEC:0001672688-26-000144:0
22,325 shares@ US$10.160.014% mcap50.8% of flowCommon StockSEC:0001672688-26-000143:0
387 shares@ US$10.160.0002% mcap0.6% of flowCommon StockSEC:0001672688-26-000141:0
8,320 shares@ US$8.710.0043% mcap10.4% of flowCommon StockSEC:0001672688-26-000138:0
12,900 shares@ US$11.540.0089% mcap100.0% of flowCommon StockSEC:0001672688-26-000124:0
Canonical exit: 28 Sept 2026 (T+90)
59,896 sharesCommon StockSEC:0001672688-26-000121:0
10,100 shares0Common StockSEC:0001672688-26-000113:0
10,100 shares0Common StockSEC:0001672688-26-000106:0
10,100 shares0Common StockSEC:0001470831-26-000526:0
10,100 shares0Common StockSEC:0001672688-26-000105:0
10,100 shares0Common StockSEC:0001672688-26-000108:0
10,100 shares0Common StockSEC:0001672688-26-000109:0
8,319 shares@ US$6.750.0037% mcap8.1% of flowCommon StockSEC:0001672688-26-000093:0
90,300 shares0Common StockSEC:0001672688-26-000058:0
135,400 shares0Common StockSEC:0001672688-26-000056:0
100,000 shares@ US$2.2954.7% of flowCommon StockSEC:0001672688-26-000049:0
Canonical exit: 10 Jun 2026 (T+90)
406,200 shares0Common StockSEC:0001672688-26-000051:0
49,600 shares0Common StockSEC:0001672688-26-000054:0
5,800 shares0Common StockSEC:0001672688-26-000043:0
1,257 shares@ US$2.800.8% of flowCommon StockSEC:0001672688-26-000035:0
90,300 shares0Common StockSEC:0001672688-26-000040:0
406,200 shares0Common StockSEC:0001672688-26-000038:0
49,600 shares0Common StockSEC:0001672688-26-000037:0
135,400 shares0Common StockSEC:0001672688-26-000036:0
8,307 shares@ US$2.743.2% of flowCommon StockSEC:0001672688-26-000029:0
25 of 98 declarations
About Absci Corp
Absci Corp (ticker: ABSI) is a U.S.-listed company on the Nasdaq exchange in the United States. For French-speaking investors, it is best viewed as a small-cap healthcare/biotech name sitting at the intersection of generative AI and drug discovery. The company describes itself as a clinical-stage biopharmaceutical company focused on designing differentiated antibody therapeutics through an AI-native platform paired with scalable wet-lab capabilities. Its headquarters are in Vancouver, Washington, with AI research labs in New York City and Serbia, plus an innovation center in Zug, Switzerland. ([investors.absci.com](https://investors.absci.com/?utm_source=openai))
Absci’s corporate history dates back to August 2011, when it was founded as an Oregon LLC. It later became a Delaware LLC in 2016 and was reorganized into a Delaware corporation in 2020. That path is consistent with a venture-backed deep-tech company evolving into a public biotech platform business. Today, Absci’s core value proposition is its “AI Drug Creation” platform, which combines generative models, antibody engineering, multiparametric optimization, and experimental validation to accelerate biologics discovery and improve candidate quality. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1672688/000162828022023604/absci-sx3.htm?utm_source=openai))
Read moreShow less
Operationally, the company is pursuing two complementary strategies. First, it is advancing its own internal pipeline of proprietary assets. The most visible programs are ABS-101, an anti-TL1A antibody being developed for inflammatory bowel disease, and ABS-201, an anti-prolactin receptor antibody aimed at androgenetic alopecia, with potential expansion into endometriosis. Second, Absci works with pharmaceutical, biotech, technology, and academic partners to validate and monetize its platform capabilities. This dual model — internal pipeline plus external partnerships — is central to its investment case and competitive positioning. ([investors.absci.com](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-fourth-quarter-and-full-1?utm_source=openai))
In competitive terms, Absci remains an early-stage company with limited operating scale and no established commercial product revenue. Its differentiation lies in the promise to shorten biologics discovery timelines, lower costs, and increase the probability of success. That said, the investment case remains highly execution-dependent, with clinical readouts, partnership wins, and capital discipline all likely to drive sentiment. Recent milestones have been meaningful: in 2025, Absci reported first dosing in Phase 1 studies for ABS-101 and Phase 1/2a studies for ABS-201; in 2026, it expanded ABS-201 into endometriosis and continued to highlight progress across its pipeline. A collaboration with Oracle and AMD to accelerate AI-driven drug discovery also underscored the company’s technology ambitions. ([investors.absci.com](https://investors.absci.com/news-releases/news-release-details/absci-announces-first-participants-dosed-phase-1-clinical-trial/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
